aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Avoro Capital Advisors is a global venture capital firm specializing in life sciences and biotechnology startups. The firm invests in publicly traded, early, and late-stage companies, focusing on scientific breakthroughs that address unmet medical needs. Avoro typically participates in various investment rounds, including Series B, Series C, and post-IPO equity, providing both financial and intellectual support throughout the investment lifecycle.
Notable portfolio companies include Aadi Bioscience, Allogene Therapeutics, Krystal Biotech, Kymera Therapeutics, Mersana Therapeutics, Scribe Therapeutics, Tango Therapeutics, and Vividion Therapeutics. Avoro's investment philosophy emphasizes identifying unique or mispriced opportunities and managing macro and company-specific risks. The firm offers a comprehensive approach to dissecting complex situations, aiming to provide substantial value-add services to its portfolio companies.
Also Known As
Raven Capital Advisors, LLC
Operating Status
Active
Avoro Capital Advisors Address
New York City,
New York
10012-3832
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts